Anesthesia for patients with a history of malignant hyperthermia

Current Opinion in Anaesthesiology

Volumn 23, Issue 3, 2010, Pages 417-422

  Wappler, Frank ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Anaesthesia; Dantrolene; Malignant hyperthermia; Propofol; Trigger

Indexed keywords

ACTIVATED CARBON; DANTROLENE; DESFLURANE; DIAZEPAM; DOXACURIUM; ENFLURANE; ETOMIDATE; HALOTHANE; HEXOBARBITAL; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; ISOFLURANE; KETAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHOHEXITAL; METHOXYFLURANE; MIDAZOLAM; MIVACURIUM; MUSCLE RELAXANT AGENT; NITROUS OXIDE; PANCURONIUM; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUXAMETHONIUM; THIOPENTAL; UNINDEXED DRUG; VECURONIUM; XENON;

ANESTHESIA; CENTRAL CORE DISEASE; DISEASE PREDISPOSITION; GENERAL ANESTHESIA; GENETIC COUNSELING; HUMAN; MALIGNANT HYPERTHERMIA; MUSCLE WEAKNESS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREMEDICATION; PREVALENCE; PRIORITY JOURNAL; REGIONAL ANESTHESIA; REVIEW; SENSITIVITY AND SPECIFICITY;

ANESTHESIA; HUMANS; MALIGNANT HYPERTHERMIA;

EID: 77951979944     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328337ffe0     Document Type: Review

References (55)

1. Wappler F. Malignant hyperthermia. Review. Eur J Anaesthesiol 2001; 18: 632-652.
2. Pessah IN, Lynch C, Gronert GA. Complex pharmacology of malignant hyperthermia. Anesthesiology 1996; 84: 1275-1279.
3. Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis 2007; 2: 21.
4. Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of •• malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110: 89-94. In this study current incidence of malignant hyperthermia and the predictors associated with in-hospital mortality in the United States was evaluated, and it has been shown that the incidence of malignant hyperthermia has increased in recent years.
5. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-1269.
6. Ørding H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and un-related low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955-966.
7. Allen GC, Larach MH, Kunselman AR. The sensitivity and specificity of the caffeine halothane contracture test: a report from the North American malignant hyperthermia registry. Anesthesiology 1998; 88: 579-588.
8. Urwyler A, Deufel T, McCarthy T, et al. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-287.
9. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. J Am Med Assoc 2005; 293: 2918-2924.
10. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779.
11. von Richthofen V, Wappler F, Scholz J, et al. Evaluation of malignant hyperthermia episodes with the clinical grading scale. Anasth Intensivmed Notfallmed Schmerzther 1998; 33: 244-249.
12. Capacchione JF, Muldoon SM. The relationship between exertional heat • illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009; 109: 1065-1069. A very interesting review on the relation between exertional heat illness as well as rhabdomyolysis and malignant hyperthermia.
13. Wingard DW. Malignant hyperthermia: a human stress syndrome? Lett Lancet 1974; II: 1450-1451.
14. Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with stress-induced rhabdomyolysis. Anesthesiology 2001; 94: 95-100.
15. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg 2009; 109: 1049-1053.
16. Treves S, Jungbluth H, Muntoni F, Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 2008; 8: 319-328.
17. Klingler W, Rueffert H, Lehmann-Horn F, et al. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009; 109: 1167-1173.
18. Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to • malignant hyperthermia. Anesth Analg 2009; 109: 1054-1064. In this review the association between malignant hyperthermia and myotonias is extensively presented.
19. Flick RP, Gleich SJ, Herr MH, Wedel DJ. The risk of malignant hyperthermia in children undergoing muscle biopsy for suspected neuromuscular disorder. Pediatr Anesth 2007; 17: 22-27.
20. Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular • dystrophies. Anesth Analg 2009; 109: 1043-1048. This article reviews the different pathology and pathophysiology of muscular dystrophies and malignant hyperthermia.
21. Wedel DJ, Iaizzo PA. Desflurane is a trigger of malignant hyperthermia in susceptible swine. Anesthesiology 1991; 74: 508-512.
22. Ducart A, Adnet P, Renaud B, et al. Malignant hyperthermia during sevoflurane administration. Anesth Analg 1995; 80: 609-611.
23. Allen GC, Brubaker CL. Human malignant hyperthermia associated with desflurane anesthesia. Anesth Analg 1998; 86: 1328-1331.
24. Girard T, Suhner M, Levano S, et al. A fulminant malignant hyperthermia episode in a patient with ryanodine receptor mutation p. Tyr522Ser. Anesth Analg 2008; 17: 1953-1955.
25. Dershwitz M, Sreter FA, Ryan JF. Ketamine does not trigger malignant hyperthermia in susceptible swine. Anesth Analg 1989; 69: 501-503.
26. Fletcher JE, Rosenberg H, Lizzo FH. Effects of droperidol, haloperidol and ketamine on halothane, succinylcholine and caffeine contractures: implications for malignant hyperthermia. Acta Anaesthesiol Scand 1989; 33: 187-192.
27. Ørding H, Hald A, Sjøntoft E. Malignant hyperthermia triggered by heating in anaesthetized pigs. Acta Anaesthesiol Scand 1985; 29: 698-701.
28. Denborough M, Hopkinson KC, O'Brien RO, Foster PS. Overheating alone can trigger malignant hyperthermia in piglets. Anaesth Intensive Care 1996; 24: 348-354.
29. Wappler F, Scholz J, Fiege M, et al. 4-Chloro-m-cresol is a trigger of malignant hyperthermia in susceptible swine. Anesthesiology 1999; 90: 1733-1740.
30. Fiege M, Wappler F, Weißhorn R, et al. Induction of malignant hyperthermia in susceptible swine by 3, 4-methylenedioxymethamphetamine ('ecstasy'). Anesthesiology 2003; 99: 1132-1136.
31. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85: 118-128.
32. Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-373.
33. Watson CB, Reierson N, Norfleet EA. Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia. Anesthesiology 1986; 65: 312-314.
34. Petroz GC, Lerman J. Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia. Anesthesiology 2002; 96: 941-946.
35. Prinzhausen H, Crawford MW, O'Rourke J. Preparation of the Dräger Primus anesthetic machine for malignant-hyperthermia susceptible patients. Can J Anesth 2006; 53: 885-890.
36. Crawford MW, Prinzhausen H, Petroz GC. Accelerating the washout of inhalational anesthetics from the Dräger Primus anesthetic workstation. Anesthesiology 2007; 106: 289-294.
37. Whitty RJ, Wong GK, Petroz GC, et al. Preparation of the Dräger Fabius GS • (workstation for malignant-hyperthermia susceptible patients). Can J Anesth 2009; 56: 497-501. This study shows that modern anaesthesia workstations have much longer washout kinetics for volatile anaesthetics than their predecessors.
38. Gunter JB, Ball J, Than-Win S. Preparation of the Dräger Fabius anesthesia • machine for the malignant-hyperthermia susceptible patient. Anesth Analg 2008; 107: 1936-1945. This study shows for the first time that the use of charcoal enables a fast and reliable cleansing of an anaesthetic workstation prior to use for a malignant hyperthermia-susceptible patient.
39. Suresh MS, Nelson TE. Malignant hyperthermia: is etomidate safe? Anesth Analg 1985; 64: 420-424.
40. Denborough M, Hopkinson KC. Propofol and malignant hyperpyrexia. Lancet 1988; 1: 191.
41. Harrison GG. Propofol in malignant hyperthermia. Lancet 1991; 337: 503.
42. Foster PS, Hopkinson KC, Denborough MA. Propofol anaesthesia in malignant hyperpyrexia susceptible swine. Clin Exp Pharmacol Physiol 1992; 19: 183-186.
43. Krivosic-Horber R, Reyfort H, Becq MC, Adnet P. Effect of propofol on the malignant hyperthermia susceptible pig model. Br J Anaesth 1989; 62: 691-693.
44. Wappler F, Rossaint R, Baumert J, et al. Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology 2007; 106: 463-471.
45. Froeba G, Mary T, Pazhur J, et al. Xenon does not trigger malignant hyperthermia in susceptible swine. Anesthesiology 1999; 91: 1047-1052.
46. Harrison GG. Porcine malignant hyperthermia. Int Anesthesiol Clin 1979; 17: 25-61.
47. Ørding H, Fonsmark L. Use of vecuronium and doxapram in patients susceptible to malignant hyperthermia. Br J Anaesth 1988; 60: 445-449.
48. Sufit RL, Kreul JF, Bellay YM, et al. Doxacurium and mivacurium do not trigger malignant hyperthermia in swine. Anesth Analg 1990; 71: 285-287.
49. Williams C, Dozier S, Ilias W, Fulfer R. Malignant hyperthermia in swine: a study of atracurium in MH-susceptible swine. Anaesthesiol Reanim 1994; 19: 23-25.
50. Murray C, Sasaki SS, Berg D. Local anesthesia and malignant hyperthermia. Dermatol Surg 1999; 25: 626-630.
51. Wingard DW, Bobko S. Failure of lidocaine to trigger porcine malignant hyperthermia. Anesth Analg 1979; 58: 99-103.
52. Matsuoka N, Fukuda I, Kira M, et al. The use of epidural ropivacaine for a gravida with disposition for malignant hyperthermia. Matsui 2004; 53: 277-279.
53. Pollock N, Langton E, Stowell K, et al. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients. Anaesth Intensive Care 2004; 32: 502-509.
54. Pollock N, Langton E, MacDonnell N, et al. Malignant hyperthermia and day stay surgery. Anaesth Intensive Care 2006; 34: 40-45.
55. Brandom BW. Ambulatory surgery and malignant hyperthermia. Curr Opin • Anaesthesiol 2009; 22: 744-747.